Human Albumin for Resuscitation in Surgical Septic Shock: A Randomized Controlled Trial (ALBUS Study)

This study will test whether giving human albumin to keep the blood albumin level above 3.5 g/dL, in addition to standard care, improves survival in patients with surgical septic shock. Septic shock is a life-threatening complication of infection that often requires urgent surgery and intensive care. Current treatment guidelines recommend intravenous fluids and medications to support blood pressure, but the best type of fluid is still uncertain. Human albumin is a natural protein in the blood that helps maintain fluid balance and has anti-inflammatory effects. Previous studies suggest that low albumin levels are linked with worse outcomes in septic patients, and that albumin infusion might improve recovery, but results are mixed and evidence in surgical septic shock patients is lacking. In this randomized controlled trial, adult patients with surgical septic shock admitted to the surgical intensive care unit will be randomly assigned to receive either standard care alone or standard care plus 20% human albumin solution for up to 3 days. The main outcome is survival at 28 days. Secondary outcomes include length of ICU and hospital stay, need for dialysis, ventilator-free days, vasopressor-free days, fluid balance, gastrointestinal recovery, and adverse reactions. The results of this study will help determine whether targeted albumin replacement is beneficial in critically ill surgical patients with septic shock and could guide future fluid resuscitation strategies.

This is a single-center, randomized, open-label, controlled trial designed to evaluate the effect of targeted albumin replacement in adult patients with surgical septic shock. The study will be conducted in the Surgical Intensive Care Unit at Siriraj Hospital, Bangkok, Thailand. Eligible patients are those aged 18 years or older admitted with surgical septic shock, defined as suspected or proven surgical infection requiring an operation or surgical intervention within 48 hours, and persisting shock despite adequate initial fluid resuscitation. After informed consent, participants will be randomized in a 1:1 ratio, using block randomization, to one of two groups: Control group: Standard sepsis management according to international guidelines, including source control, broad-spectrum antibiotics, intravenous crystalloids, vasopressors, and other adjunctive therapies as required. Intervention group: Standard care plus intravenous 20% human albumin solution, given for up to 72 hours, with dosing guided by serum albumin levels to maintain concentrations above 3.5 g/dL. The primary endpoint is 28-day all-cause mortality. Secondary endpoints include length of ICU and hospital stay, ventilator-free days, vasopressor-free days, 7-day cumulative fluid balance, acute kidney injury requiring renal replacement therapy, recovery of gastrointestinal function, and adverse reactions. The planned sample size is 304 patients (152 per arm), which provides 80% power to detect a relative risk reduction of 40% in 28-day mortality (from 35% to 20%) with two-sided alpha of 0.05, accounting for 10% attrition. Data will be analyzed primarily on an intention-to-treat basis. Interim analysis is planned after 50% enrollment to assess safety and efficacy. Both frequentist and Bayesian approaches will be applied, including logistic regression to adjust for baseline imbalances if needed. This trial will provide evidence on whether maintaining serum albumin above 3.5 g/dL with human albumin infusion improves survival and clinical outcomes in critically ill patients with surgical septic shock.